An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
Overview
The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: March 2006
Interventions
- Drug: Cetuximab
- IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.
Arms, Groups and Cohorts
- Experimental: A
Clinical Trial Outcome Measures
Primary Measures
- Prediction of response to Erbitux with non small cell lung cancer
Secondary Measures
- Radiographic Response
Participating in This Clinical Trial
Inclusion Criteria
- Measurable disease tumor available for biopsies – Life expectancy of at least 3 months Exclusion Criteria:
- Known or documented brain metastases prior to Cetuximab therapy
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Eli Lilly and Company
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon – Fri 9 AM – 5 PM Eastern time (UTC/GMT – 5 hours, EST), Study Director, Eli Lilly and Company
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.